MyFinsight
Home
Blog
About
Proceeds from maturities
of...
$39,500K
(-6.76%↓ Y/Y)
Proceeds from exercise of
stock options
$91K
Net cash provided by
investing activities
$23,237K
(55.35%↑ Y/Y)
Net cash provided by
financing activities
$91K
Canceled cashflow
$16,263K
Net change in cash
and cash...
$651K
(123.63%↑ Y/Y)
Canceled cashflow
$22,677K
Purchase of
available-for-sale short-term...
$16,263K
(-40.65%↓ Y/Y)
Change in fair value of
warrant liabilities
$9,623K
(143.05%↑ Y/Y)
Stock-based compensation
$3,154K
(17.07%↑ Y/Y)
Non-cash lease expense
$85K
(10.39%↑ Y/Y)
Net cash used in
operating activities
-$22,677K
(-28.02%↓ Y/Y)
Canceled cashflow
$12,862K
Net loss
-$31,630K
(-78.59%↓ Y/Y)
Prepaid expenses and
other assets
$1,845K
(86.55%↑ Y/Y)
Accounts payable,
accrued expenses and...
-$1,681K
(-137.17%↓ Y/Y)
Accretion of investment
discounts
-$295K
(31.71%↑ Y/Y)
Operating lease
liabilities
-$88K
(-14.29%↓ Y/Y)
Back
Back
Cash Flow
Eledon Pharmaceuticals, Inc. (ELDN)
Eledon Pharmaceuticals, Inc. (ELDN)
source: myfinsight.com